Trial Profile
Evaluation of Effectiveness and Safety of Promus Element in Routine Clinical Practice; A Multicenter, Prospective, Observational Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms IRIS-ELEMENT
- 19 Jul 2017 Status changed from active, no longer recruiting to completed.
- 22 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Oct 2017.
- 13 May 2011 New trial record